Stockholm, Sweden & Cambridge, Mass. October 13, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Chardan Healthcare Conference.
Location: Lotte New York Palace, New York
Format: Panel discussion and 1×1 meetings
Panel: Idiopathic Pulmonary Fibrosis & Chronic Respiratory Disease: Antifibrotics, CF, Bronchiectasis & COPD Innovation
Date and time: Tuesday, October 20, 2026, 2:00–2:30 PM ET
Participant: Ahmed Mousa, CEO
Webcast: Link
For further information, please contact:
Hans Jeppsson, CFO, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com